TRACON Pharmaceuticals (NASDAQ:TCON) Research Coverage Started at StockNews.com

StockNews.com initiated coverage on shares of TRACON Pharmaceuticals (NASDAQ:TCON) in a research report report published on Tuesday. The firm issued a hold rating on the biopharmaceutical company’s stock.

TRACON Pharmaceuticals Stock Performance

Shares of NASDAQ:TCON opened at $0.05 on Tuesday. The firm has a fifty day moving average price of $0.09 and a 200 day moving average price of $0.68. TRACON Pharmaceuticals has a fifty-two week low of $0.00 and a fifty-two week high of $14.75. The firm has a market cap of $163,652.72, a price-to-earnings ratio of 0.01 and a beta of 1.43.

TRACON Pharmaceuticals (NASDAQ:TCON) last issued its earnings results on Tuesday, August 13th. The biopharmaceutical company reported ($0.94) earnings per share for the quarter. The company had revenue of $0.06 million for the quarter.

TRACON Pharmaceuticals Company Profile

TRACON Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel targeted therapeutics for cancer in the United States. Its clinical stage products include envafolimab (KN035), a PD-L1 single-domain antibody for the treatment of refractory soft tissue sarcoma; and YH001, an investigational humanized cytotoxic T-lymphocyte-associated protein 4 IgG1 monoclonal antibody that is in Phase I clinical trial for the treatment of various cancer indications.